{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T21:47:15Z","timestamp":1784238435179,"version":"3.55.0"},"reference-count":28,"publisher":"Hindawi Limited","issue":"12","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":3217,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1111\/j.1742-1241.2006.01187.x","type":"journal-article","created":{"date-parts":[[2006,11,10]],"date-time":"2006-11-10T11:24:25Z","timestamp":1163157865000},"page":"1647-1653","source":"Crossref","is-referenced-by-count":17,"title":["Pramlintide in the treatment of diabetes"],"prefix":"10.1155","volume":"60","author":[{"given":"S. V.","family":"EDELMAN","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"DARSOW","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. P.","family":"FRIAS","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"98","published-online":{"date-parts":[[2006,11,10]]},"reference":[{"key":"10.1111\/j.1742-1241.2006.01187.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJM199309303291401","article-title":"The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus","volume":"329","author":"The Diabetes Control and Complications Trial Research Group","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1742-1241.2006.01187.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/bmj.321.7258.405","article-title":"Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study","volume":"321","author":"Stratton","year":"2000","journal-title":"BMJ"},{"key":"10.1111\/j.1742-1241.2006.01187.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1056\/NEJMoa052187","article-title":"Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes","volume":"353","author":"Nathan","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1742-1241.2006.01187.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/S0002-9343(02)01176-2","article-title":"Novel insulins: expanding options in diabetes management","volume":"113","author":"Gerich","year":"2002","journal-title":"Am J Med"},{"key":"10.1111\/j.1742-1241.2006.01187.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.2174\/138955705774575273","article-title":"Non-insulin dependent diabetes mellitus: present therapies and new drug targets","volume":"5","author":"Das","year":"2005","journal-title":"Mini Rev Med Chem"},{"key":"10.1111\/j.1742-1241.2006.01187.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1089\/15209150260007390","article-title":"Unresolved challenges with insulin therapy in type 1 and type 2 diabetes: potential benefit of replacing amylin, a second beta-cell hormone","volume":"4","author":"Edelman","year":"2002","journal-title":"Diabetes Technol Ther"},{"key":"10.1111\/j.1742-1241.2006.01187.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2165\/00024677-200302010-00004","article-title":"Weight effects of current and experimental drugs for diabetes mellitus","volume":"2","author":"Purnell","year":"2003","journal-title":"Treat Endocrinol"},{"key":"10.1111\/j.1742-1241.2006.01187.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1001\/jama.280.2.140","article-title":"Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the DCCT. Diabetes Control and Complications Trial","volume":"280","author":"Purnell","year":"1998","journal-title":"JAMA"},{"key":"10.1111\/j.1742-1241.2006.01187.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.2337\/diacare.20.11.1744","article-title":"The prevention and treatment of obesity. Application to type 2 diabetes","volume":"20","author":"Maggio","year":"1997","journal-title":"Diabetes Care"},{"key":"10.1111\/j.1742-1241.2006.01187.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1097\/00060793-199708000-00006","article-title":"Amylin's physiology and its role in diabetes","volume":"4","author":"Young","year":"1997","journal-title":"Curr Opin Endocrinol Diabetes"},{"key":"10.1111\/j.1742-1241.2006.01187.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.2165\/00003495-200464130-00003","article-title":"Pramlintide for the treatment of insulin-requiring diabetes mellitus: rationale and review of clinical data","volume":"64","author":"Kruger","year":"2004","journal-title":"Drugs"},{"key":"10.1111\/j.1742-1241.2006.01187.x-BIB12|cit12","unstructured":"[SYMLIN \u00ae ] Amylin Pharmaceuticals, Inc. 2005 SYMLIN prescribing information Amylin Pharmaceuticals, Inc http:\/\/symlin.com\/pdf\/SYMLIN-pi-combined.pdf"},{"key":"10.1111\/j.1742-1241.2006.01187.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.2337\/diacare.26.11.3074","article-title":"Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: a dose-timing study","volume":"26","author":"Weyer","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1111\/j.1742-1241.2006.01187.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/dmrr.419","article-title":"Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose-timing study","volume":"20","author":"Maggs","year":"2004","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1111\/j.1742-1241.2006.01187.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2337\/diacare.26.1.1","article-title":"Impact of pramlintide on glucose fluctuations and postprandial glucose, glucagon, and triglyceride excursions among patients with type 1 diabetes intensively treated with insulin pumps","volume":"26","author":"Levetan","year":"2003","journal-title":"Diabetes Care"},{"issue":"Suppl. 1","key":"10.1111\/j.1742-1241.2006.01187.x-BIB16|cit16","first-page":"A12","article-title":"In an open-label clinical study pramlintide lowered A1c, body weight, and insulin use in patients with type 2 diabetes failing to achieve glycemic targets with insulin therapy","volume":"54","author":"Karl","year":"2005","journal-title":"Diabetes"},{"issue":"Suppl. 1","key":"10.1111\/j.1742-1241.2006.01187.x-BIB17|cit17","first-page":"A118","article-title":"In an open-label clinical study pramlintide lowered A1C, body weight, and insulin use in patients with type 1 diabetes failing to achieve glycemic targets with insulin therapy","volume":"54","author":"Guthrie","year":"2005","journal-title":"Diabetes"},{"key":"10.1111\/j.1742-1241.2006.01187.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"881","DOI":"10.2337\/diacare.26.3.881","article-title":"Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c)","volume":"26","author":"Monnier","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1111\/j.1742-1241.2006.01187.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"724","DOI":"10.2337\/diacare.25.4.724","article-title":"A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes","volume":"25","author":"Whitehouse","year":"2002","journal-title":"Diabetes Care"},{"key":"10.1111\/j.1742-1241.2006.01187.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"784","DOI":"10.2337\/diacare.26.3.784","article-title":"Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial","volume":"26","author":"Hollander","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1111\/j.1742-1241.2006.01187.x-BIB21|cit21","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1111\/j.1464-5491.2004.01319.x","article-title":"Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial","volume":"21","author":"Ratner","year":"2004","journal-title":"Diabet Med"},{"key":"10.1111\/j.1742-1241.2006.01187.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1089\/15209150252924094","article-title":"Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes","volume":"4","author":"Ratner","year":"2002","journal-title":"Diabetes Technol Ther"},{"key":"10.1111\/j.1742-1241.2006.01187.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/00000441-200104000-00002","article-title":"Obesity and coronary heart disease","volume":"321","author":"Alexander","year":"2001","journal-title":"Am J Med Sci"},{"issue":"Suppl. 4","key":"10.1111\/j.1742-1241.2006.01187.x-BIB24|cit24","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1038\/sj.ijo.0802215","article-title":"Updated review on the benefits of weight loss","volume":"26","author":"Vidal","year":"2002","journal-title":"Int J Obes"},{"key":"10.1111\/j.1742-1241.2006.01187.x-BIB25|cit25","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1001\/jama.295.2.190","article-title":"Midlife body mass index and hospitalization and mortality in older age","volume":"295","author":"Yan","year":"2006","journal-title":"JAMA"},{"key":"10.1111\/j.1742-1241.2006.01187.x-BIB26|cit26","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.2337\/diacare.23.10.1499","article-title":"Intentional weight loss and mortality among overweight individuals with diabetes","volume":"23","author":"Williamson","year":"2000","journal-title":"Diabetes Care"},{"key":"10.1111\/j.1742-1241.2006.01187.x-BIB27|cit27","first-page":"397","article-title":"Beneficial health effects of modest weight loss","volume":"16","author":"Goldstein","year":"1992","journal-title":"Int J Obes"},{"key":"10.1111\/j.1742-1241.2006.01187.x-BIB28|cit28","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/oby.2004.76","article-title":"Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients","volume":"12","author":"Hollander","year":"2004","journal-title":"Obes Res"}],"container-title":["International Journal of Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1742-1241.2006.01187.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1742-1241.2006.01187.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T06:04:41Z","timestamp":1643349881000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1742-1241.2006.01187.x"}},"subtitle":["DIABETES TREATMENT WITH PRAMLINTIDE"],"short-title":[],"issued":{"date-parts":[[2006,11,10]]},"references-count":28,"journal-issue":{"issue":"12"},"URL":"https:\/\/doi.org\/10.1111\/j.1742-1241.2006.01187.x","relation":{},"ISSN":["1368-5031"],"issn-type":[{"value":"1368-5031","type":"print"}],"subject":[],"published":{"date-parts":[[2006,11,10]]}}}